Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:PMC

Pharmerica (PMC) Stock Price, News & Analysis

Pharmerica logo

About Pharmerica Stock (NYSE:PMC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
283,015 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. Its segments include institutional pharmacy, which provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings; specialty infusion services, which provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings, and specialty oncology pharmacy, which provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.

Receive PMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmerica and its competitors with MarketBeat's FREE daily newsletter.

PMC Stock News Headlines

Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
Activities of Daily Living for Seniors
Golden Living
See More Headlines

PMC Stock Analysis - Frequently Asked Questions

Pharmerica Co. (NYSE:PMC) released its quarterly earnings results on Thursday, November, 9th. The company reported $0.46 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by $0.03. The company earned $595.10 million during the quarter, compared to analysts' expectations of $596.80 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmerica investors own include Cencora (COR), Capitol Federal Financial (CFFN), Bristol-Myers Squibb (BMY), Tesla (TSLA), Depomed (DEPO), Inovio Pharmaceuticals (INO) and Bioblast Pharma (ORPN).

Company Calendar

Last Earnings
11/09/2017
Today
6/05/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
N/A
Industry
N/A
Sub-Industry
Health Care Distributors
Current Symbol
NYSE:PMC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:PMC) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners